Home
About SAMA
Milestone
About SAMA
PCT application new technology for SEA™( SAMA’s Enhanced Absorption : National stage entry in 11 countries including EU
IND approval of Phase 1 clinical trial for PRIC (Incrementally modified drug, Asthma in pediatrics)
Launched CITUS™ tablets
(Incrementally modified drug, the world’s lowest dosage form by improvement of bioavailability)
Completion of Phase 2 clinical trial for SA09012 (The first new drug in Leukotriene receptor antagonists(LTRAs) since Montelukast (4th generation LTRAs))
Completion of Phase 1 clinical trial for CITUS™ tablet (22% dose reduction compared to the original product in Japan by improving bioavailability)
License agreement signed with Emcure of India for a new treatment for GERD
Approval of Accreditation of Foreign Manufacturer (FMA) by PMDA
PCT application for new technology ‘IDIA™ (Instant Dissolving, Immediate Absorption) : National stage entry in 11 countries including Europe
Approval of new indication (perennial allergy rhinitis) for CITUS™ dispersible tablets
IND approval of phase 2 clinical trial for SA09012 by MFDS
Launched VIASIN® IDIA in Korea
Approval of world’s first new indication (allergy rhinitis in pediatrics) for CITUS™ dry syrup
License agreement signed with Mitsubishi Tanabe Pharma of Japan for a treatment for bronchial asthma
Technology alliance agreement with Inventia Laboratories of India(Aceclofenac SR) and Frutarom of Switzerland (Hebron)
Mr. Jun Hur appointed as CEO and Chairman of SAMA
Listed in KOSDAQ
